$IRD

YERXA BENJAMIN R sold $22K of IRD

YERXA BENJAMIN R (President) sold 7,429 shares of Opus Genetics, Inc. (IRD) at $2.97 on 2026-07-23.

Original reporting
SEC EDGAR · YERXA BENJAMIN R
Published Jul 27, 2026, 8:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 27, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRD
Neutral
medium confidence
Mentioned
$IRD
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRDNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details by the President, including shares, price, and post-transaction holdings. The disclosure does not provide new operational or financial information about the company.

02

Market read

Traders may note insider selling as a minor sentiment datapoint, but the transaction size is small and lacks fundamental drivers.

03

What to watch

No 10b5-1 plan is stated, but the article provides no context on taxes, option exercises, or prior planned sales, limiting inference.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-27, transaction dated 2026-07-23.

Background

This is an SEC Form 4 insider transaction disclosure for Opus Genetics, Inc. (IRD).

Company-level read

Ticker impact

$IRDNeutralMedium confidence
Context

Opus Genetics insider Form 4 shows President sold 7,429 shares at $2.97 on 2026-07-23, totaling about $22.1K.

Expected impact

Likely limited near-term price impact; any effect is sentiment-only and typically fades.

Evidence & confidence

The filing is a disclosed transaction size of roughly $22K and does not include new company performance, guidance, or material corporate events.

Market effects

No clear sector read-through from a small, routine insider sale.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or personal liquidity needs and may not signal reduced confidence, especially with a small value.

Key entities

  • Opus Genetics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • YERXA BENJAMIN R

    President, officer/director, reported open-market sale of shares.

Related articles

$IRDMed

Opus Genetics, Inc.: Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update

Opus Genetics (Nasdaq: IRD) reported Q2 2026 results for the quarter ended June 30, 2026. Cash was $88.8 million, expected to fund operations into 2029. Revenue fell to $0.8 million from $2.9 million. R&D rose to $11.2 million. Net loss was $8.1 million. The company also updated clinical timelines for OPGx-BEST1, OPGx-LCA5, and other programs.

$IRDMed

Opus Genetics, Inc.: Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

Opus Genetics (Nasdaq: IRD) updated its OPGx-BEST1 Phase 1/2 trial (BIRD-1) for BEST1-associated inherited retinal diseases. Cohort 1 enrollment (5 participants) is complete, with Month 3 data expected in the second week of September 2026. The company plans to present at EURETINA in October 2026 and submit Month 3 results to the FDA for next steps.